Novartis licenses out early antiviral work to Gilead

Novartis licenses out early antiviral work to Gilead

Source: 
Fierce Biotech
snippet: 

Just two days after announcing its R&D chief was stepping down, Gilead Sciences has announced it will be buying up a few of Novartis’ unwanted early-stage infection assets.